Boston, MA 03/20/2014 (wallstreetpr) – Taglich Brothers, a New York based investment research firm has started coverage on CollabRx Inc (NASDAQ:CLRX). The firm’s analyst Juan Noble has placed a speculative buy rating on the company while assigning a price target of $10 for the period of next one year. This price target represents a potential 188% increase in value over the company’s current market price of $3.47. On contrary to the most of the genomic laboratories, which pile together in-house analytics with thetest results, CollabRx is rather a pure Bioinformatics company. CollabRx Inc (NASDAQ:CLRX) has designed a specialized medical database that is regularly updated by software systems, releasing into arange of online medical and scientific resources.
China Digital TV Holding Co., Ltd.(ADR) (NYSE:STV) appears to be appearing from the slumber of downfall that it witnessed in its most recent days. During the beginning of March’ 2014, China Digital TV tumbled steeply as it announced its fresh financials. While its revenue and profitability during the last reported quarter came on strong, but its weak revenue guidance resulted in its slump. For the last quarter, China Digital TV Holding Co., Ltd.(ADR) (NYSE:STV), which provides conditional access systems in the digital television market, reported revenue increase of 12% and two-fold increase in its profitability.
Synthetic Biologics Inc (NYSEMKT:SYN) receives an upgrade from the analyst at Maxim Group, who have doubled their price target for it from $3 to $6 now. The analysts believe that the company has multiple catalysts lay up ahead for it. The analysts noted that post their meeting with the company’s management on Tuesday, they conclude that the company has several events lined up ahead, which includes Trimesta top-line data to come in April. Additionally, SYN-004 to start for phase 1b/2 trial and SYN005for pertussis has displayed an impressive data. Moreover, SYN-010 and SYN-001 are other catalysts, which could drive the stock this year.
